Post-procedure dose ok after hours. 12 hours (q 24h dosing only) assuming surgical hemostasis; second dose 24 hours after first dose.

Similar documents
Anticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017

Antiplatelet and Anticoagulant Therapy Management Surrounding Regional Anesthesia

Guidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults

ADVOCATE HEALTHCARE GUIDELINE FOR ANTITHROMBOTIC REVERSAL

Antiplatelets and Anticoagulants. Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center

Title: RN Specialty Practice: RN Procedure: Epidural Catheter Removal. I.D. Number: 1080

Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol

Prostate Biopsy Alerts

DEEP VEIN THROMBOSIS (DVT): TREATMENT

Nanik Hatsakorzian Pharm.D/MPH

Emergent Anticoagulation Reversal

Index. Hematol Oncol Clin N Am 19 (2005) Note: Page numbers of article titles are in boldface type.

Change from lovenox to pradaxa

Funding: The ASRA Consensus Conference was funded by unrestricted educational grants from: Pharmacia & Upjohn Company and Aventis Pharmaceuticals

Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015

VENOUS THROMBOEMBOLISM PHARMACOLOGY. University of Hawai i Hilo DNP Program NURS 603 Advanced Clinical Pharmacology Danita Narciso Pharm D

Acute Coronary Syndrome refers to any

Blood Thinner Agent. Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy

Hemostasis and Blood Forming Organs

EAU GUIDELINES ON THROMBOPROPHYLAXIS IN UROLOGICAL SURGERY

Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine

Management of antithrombotic agents before endoscopy 삼성서울병원소화기내과임상강사이세옥

NEURAXIAL BLOCKADE AND ANTICOAGULANTS

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

MANAGEMENT OF OVER-ANTICOAGULATION. Tammy K. Chung, Pharm.D. Critical Care & Cardiology Specialist Presbyterian Hospital Dallas

Clinical Guideline for Anticoagulation in VTE

Asif Serajian DO FACC FSCAI

Disclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose

Appendix IV - Prescribing Guidance for Apixaban

THROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY

ADMINISTRATIVE CLINICAL Page 1 of 6

Consensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture

Appendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS

Update in Perioperative Anticoagulation and Antiplatelet management

COPYRIGHTED MATERIAL. Index

ATLANTIC HEALTH GUIDELINES FOR ANTICOAGULANT, ANTIPLATELET, AND THROMBOLYTIC REVERSAL IN ADULT PATIENTS

PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT

Robotic Whipple or Distal Pancreatectomy and Splenectomy

Antithrombotics 201: Aspirin and USPSTF. Presented by: Craig Williams, PharmD., BCPS., FNLA; November, Conflicts of Interest: None

Reducing the Use of Reversal Agents in a Community Hospital

Xarelto (rivaroxaban)

Obesity, renal failure, HIT: which anticoagulant to use?

Reversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016

Novel Anticoagulation Therapy in Acute Coronary Syndrome

on Anti-coagulants -- Is It Safe? And When to Stop?

Thyroid or Parathyroid Surgery

Anticoagulation Update David J. Moliterno, MD

Miralax (Polyethyene Glycol) Bowel Prep

Updates in Management of Venous Thromboembolic Disease

Razvana Akbar Anticoagulation Pharmacist LTH

Razvana Akbar Anticoagulation Pharmacist LTH

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center

Update on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell

ANTICOAGULATION RELATED BLEEDING - GUIDELINE SUMMARY

VTE Prevention After Hip or Knee Replacement

Endoscopy in the Era of Anti- Platelet and Anti-Coagulation

2017 Oregon Dental Conference Course Handout

emeasure Title Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older

Top 5 (or so) Hematology Consults. Tom DeLoughery, MD FACP FAWM. Oregon Health and Sciences University DISCLOSURE

Clinical issues which drug for which patient

Treatment Options and How They Work

Tailoring adjunctive antithrombotic therapy to reperfusion strategy in STEMI

Novel Oral An,coagulants: Prac,cal Aspects. Caroline Berube, MD Clinical Associate Professor Division of Hematology November 2015

Index. interventional.theclinics.com. Note: Page numbers of article titles are in boldface type.

Targeting a Network Anticoagulation Issue. Anthony J. Macchiavelli, M.D., FHM

G02.2A Transport Office of the Medical Director TRANSPORT TO THE COMPREHENSIVE STROKE CENTER (HSC) Implementation date October 30, 2018

THROMBOTIC DISORDERS: The Final Frontier

Anticoagulants: Agents, Pharmacology and Reversal

NOACS/DOACS*: COAGULATION TESTS

UW MEDICINE PATIENT EDUCATION. Treating Blood Clots. What is a blood clot? DRAFT

Emergency Treatment of Ischemic Stroke

D E A R. W Aspirin. AF New Anticoagulants: Todays Aims

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center

Treatments for stroke prevention in Atrial Fibrillation as recommended by the Canadian Cardiovascular Society

ANTI COAGULATION AND BLOCKS

The Management Of Regional Analgesia Using A Nerve Catheter. Lead Nurse Acute Pain Specialist Nurse CLINICAL GUIDELINE

Peri-Procedural Management of Antithrombotic Agents

Hot Topics: Transitions of Care

New Age Anticoagulants: Bleeding Considerations

Who uses these medications? Assessing Patients Who Take Blood-Altering Medications. 3 Types of Acute Coronary Syndromes. Platelet-Related Fatalities

Injection Sclerotherapy for Venous Malformations

Advances in Anticoagulation

Conflicts of Interest: None. Aspirin, primary prevention and USPSTF. Primary prevention of ASCVD is important

Novel Anticoagulant Drugs. by: Dr. M. Kamandi Fellowship of hematology and Oncology

Xarelto (rivaroxaban) Prescriber Guide

Tarkten A Pharr, MD, FACS 04/26/2018. VTE Prevention Strategies: Is a One Size Fits all Approach Correct?

Anticoagulation

Managing Perioperative Anticoagulation. Edie Shen MD

GENICULAR NERVE ABLATION

Supplementary Online Content

Miralax (Polyethylene Glycol) Bow el Prep (Diabetic)

Comparison of novel oral anticoagulants (NOACs)

Direct Oral Anticoagulants

Stolling en anesthesie. Erik Vandermeulen MD, PhD Dept. of Anesthesia

Agents for Peripheral Vascular Disease & Thrombosis

Agents for Peripheral Vascular Disease & Thrombosis

NEW ZEALAND DATASHEET

Leading the Charge in Anticoagulation Reversal: Benefits, Risks, and Key Factors in Application to the Traumatically Injured Patient

ANTICOAGULANTS & FIBRINOLYTIC AGENTS Chapter 34

Disclosure Slide. Controversies in Anticoagulation. Presenter Disclosure Information. Challenges in Anticoagulation

Transcription:

Medication Time to wait after last dose Post-procedure dose ok after hours Can pull catheter hours after last dose Can give next dose hours after pulling catheter Enoxaparin (Lovenox) Prophylactic dose (30-40mg)* 12 hours for either q24h or q12h dosing of enoxaparin 12 hours (q 24h dosing only) assuming surgical hemostasis; second dose 24 hours after first dose. 12 hours (q 24h only) 4 hours [Check platelet count if enoxaparin given for more than 3-4 days] LMWH therapeutic doses (enoxaparin 1ml/kg q 12h, dalteparin 120U/kg q 12h, dalteparin 200U/kg q day, tinzaparin 175 U/kg q day) 24 hours Consider checking anti-factor Xa activity level (esp in elderly and renal pts) Contraindicated Contraindicated Likely 24 hours Heparin low-dose subcutaneous ** -No delay required if initial dose -4 hours if q12h or q8h dosing No delay required (for either q12h or 4 hours (for either q12h or No delay required (for either q12h or [Check platelet count if heparin given for more than 3-4 days] Heparin higherdose 7500-10,000 U SC BID or daily dose <20,000 U 12 hours; check PTT < 40 can use low-dose heparin instead 4 hours after last dose of low-dose heparin No delay required; count if appropriate Heparin therapeutic (individual dose >10,000 U SC per dose or >20,000 U total daily dose) 24 hours; check PTT < 40 can use low-dose heparin instead 4 hours after last dose of low-dose heparin No delay required; count if appropriate

Ticagrelor (Brilinta) 5-7 days Contraindicated Contraindicated Can be done Prasugrel (Effient) 7-10 days Contraindicated Contraindicated Can be done Clopidogrel (Plavix) 5-7 days Catheter can be maintained only if no loading dose No recommendation Can be done Ticlopidine (Ticlid) 10 days Catheter can be maintained only if no loading dose No recommendation Can be done Warfarin*** 5 days and normal INR Usually not recommended. However, may be reasonable to start if: -low dose -monitor INR <1.5 daily When INR <1.5 if warfarin being administered in low dose No wait required since slow pharmacodynamics Avoid concurrent medications that increase risk of bleeding -routine neurological checks

Heparin infusion 2-4 hours after discontinuation; check PTT<40 Contraindicated Contraindicated 1-2 hours Fondaparinux No official recommendations, but based on pharmacology, likely 48 hours if less than 2.5mg qday, or 72 hours if 5-10mg qday. Longer in renal impairment Contraindicated Contraindicated No recommendations Rivaroxaban (Xarelto); Apixiban (Eliquis); Edoxaban (Savaysa) 72 hours; consider checking antifactor Xa activity level if less than 72 hours Not recommended Not recommended. If inadvertent rivaroxaban or apixaban hold for 24-30 hours and check anti-factor Xa activity prior to removal 6 hours Betrixaban (Bevyxxa) 72 hours; consider checking betrixaban or antifactor Xa level if less than 72 hours Contraindicated if inadvertent hold for 72 hours prior to removal 5 hours Dabigatran (Pradaxa) 5 days. However, if no bleeding risk factors: -72 hours if CrCl >= 80ml/min -96 hours if CrCl 50-79ml/min (consider checking DTT or ECT) Contraindicated if inadvertent hold 34-36 hours, consider checking dtt or ECT prior to removal 6 hours

-120 hours if CrCl 30-49ml/min -contraindicated in pts with CrCl <30ml/min Argatroban; Lepirudin; Desirudin; Bivalirudin Check PTT <40 Contraindicated Contraindicated Unknown Abciximab Eptifibatide Tirofiban 48-72 hours; Likely 8 hours; Check platelet Likely 8 hours; Check platelet Cilostazol Likely 48 hours Contraindicated Contraindicated 6 hours Thrombolytics: Alteplase (tpa); releplase; tenecteplase; streptokinase No data. Check PT/PTT/INR/ Fibrinogen Contraindicated Contraindicated No recommendations. May be as long as 10 days. Dipyridamole 24 hours Contraindicated Contraindicated 6 hours Cangrelor (P2Y12 inhibitor) Aspirin, NSAIDS, COX 2 Plexus or peripheral nerve block technique anticoagulant recommendations: 3 hours Contraindicated Contraindicated 8 hours No time restrictions for catheter placement or removal, but exercise caution if more than one agent is being administered concurrently Management based on site compressibility, vascularity, and consequences of bleeding.

*Note neuroaxial/deep plexus techniques should not be attempted nor catheters maintained in patients on therapeutic doses (1mg/kg) of enoxaparin **Note: subcutaneous heparin may be given every 8 hours in patients with neuroaxial catheters ***For simplicity we recommend removing all neuroaxial/deep plexus catheters prior to starting warfarin. However, initial doses of warfarin render a patient hypercoagulable and if the surgical team desires to give an initial dose of warfarin with a neuroaxial catheter, this is not unreasonable. SOURCE: AMERICAN SOCIETY OF REGIONAL ANESTHESIA. Reg Anesth Pain Med 2018; 43:263-309.